The Role of ERO1α in Modulating Cancer Progression and Immune Escape

Brennan D. Johnson¹, Werner J. Geldenhuys²,³, Lori A. Hazlehurst¹,²,*

¹WVU Cancer Institute, Morgantown, WV 26506, USA
²WVU School of Pharmacy, Morgantown, WV, 25606, USA
³WVU Neuroscience Institute, Morgantown, WV, 25606, USA

Abstract

Endoplasmic reticulum oxidoreductin-1 alpha (ERO1α) was originally shown to be an endoplasmic reticulum (ER) resident protein undergoing oxidative cycles in concert with protein disulfide isomerase (PDI) to promote proper protein folding and to maintain homeostasis within the ER. ERO1α belongs to the flavoprotein family containing a flavin adenine dinucleotide utilized in transferring of electrons during oxidation-reduction cycles. This family is used to maintain redox potentials and protein homeostasis within the ER. ERO1α’s location and function has since been shown to exist beyond the ER. Originally thought to exist solely in the ER, it has since been found to exist in the golgi apparatus, as well as in exosomes purified from patient samples. Besides aiding in protein folding of transmembrane and secretory proteins in conjunction with PDI, ERO1α is also known for formation of de novo disulfide bridges. Public databases, such as the Cancer Genome Atlas (TCGA) and The Protein Atlas, reveal ERO1α as a poor prognostic marker in multiple disease settings. Recent evidence indicates that ERO1α expression in tumor cells is a critical determinant of metastasis. However, the impact of increased ERO1α expression in tumor cells extends into the tumor microenvironment. Secretory proteins requiring ERO1α expression for proper folding have been implicated as being involved in immune escape through promotion of upregulation of programmed death ligand-1 (PD-L1) and stimulation of polymorphonuclear myeloid derived suppressor cells (PMN-MDSC’s) via secretion of granulocytic colony stimulating factor (G-CSF). Hereby, ERO1α plays a pivotal role in cancer progression and potentially immune escape; making ERO1α an emerging attractive putative target for the treatment of cancer.

Keywords

ERO1; Cancer; ER stress; Cancer therapeutics; Immune resistance
Introduction

The failure to eradicate minimal residual disease often located at metastatic sites and/or the bone marrow niche continues to be a clinical barrier for successful treatments in cancer [1–4]. Unfortunately, in some tumor’s disease relapse is associated with a multi-drug resistant phenotype that corresponds to resistance to structurally and functionally divergent agents. Similar to conventional therapies the success of immune-oncology is limited to the occurrence of primary resistance in some patients, as well as emergence of acquired resistance [5]. Accumulating experimental evidence indicates that the tumor microenvironment plays a critical role in mediating sensitivity to targeted agents as well as immunotherapy [6,7]. Thus, to improve the gap in patient outcomes new targets need to be validated in the context of the metastatic phenotype and the tumor microenvironment. This review will discuss the potential of ERO1α as target for the treatment of cancer. Despite the endoplasmic reticulum being one of the largest cellular organelles, it was one of the last ones discovered [8]. Originally described by Emilio Veratti in 1902, it was not until the electron microscope was available that George Palade and Keith Porter made the rediscovery [9–11] capturing the structural complexities and tubular structure existing in the cytoplasm [12]. Since the re-discovery, the ER has been identified to be a continuous membranous organelle essential for protein folding, calcium storage, lipid metabolism, protein transport, post-translational modifications, and protein transport via vesicles [13]. It is composed of two main parts; smooth ER and rough ER. The rough ER is composed of ribosomes and continuous cisternae that have an important role in protein folding and storage, while the smooth ER is void of ribosomes and composed mainly of microtubules, and is critical for synthesis and storage of lipids. Maintaining homeostasis within the ER is essential for proper formation of desulphated bridges and ultimately, protein folding [14]. A major determinant of homeostasis occurs through oxidative enzymes of the flavin dependent endoplasmic reticulum oxidoreductin-1 (ERO1α) family [15–19] and by the buffering capacity of reduced glutathione (GSH) and oxidized glutathione (GSSG) in a 3:1–6:1 molar ratio in favor of reduced glutathione [20–22]. ERO1α is known to oxidize protein disulfide isomerase (PDI) in order to form de novo disulfide bridges [16]. The crucial function of disulfide bridging occurring in the ER between ERO1α and PDI have been well-established [23]. Briefly, the target unfolded protein within the ER can be oxidized by PDI resulting in the reduction of PDI. Oxidized ERO1α can in turn lead to the recycling of PDI to the oxidized from. Reduced ERO1α can be oxidized and form de-novo disulfide bridge utilizing FAD as a cofactor leading to FADH and reduction of molecular oxygen to ROS (See Figure 1).

Cancer cells typically are under increased levels of ER stress. ER stress is most evident in secretory tumors such as multiple myeloma, breast, lung and pancreatic. However, other inducers of ER stress include hypoxia and chemotherapy. Given the importance of ER homeostasis, ERO1α-PDI interaction, and formation of de novo disulfide bridges ERO1α has emerged as a player in the regulation and tolerance of cancer cells to ER stress [24]. An increase in ER-stress can lead to two possible outcomes: 1.) unfolded protein response (UPR) once activated ultimately brings ER stress back to homeostasis via inhibition of translation and inducing cell cycle arrest, or 2.) if ER stress is not resolved than apoptosis
occurs through release of cytochrome C and caspase activation, ultimately protecting the organism from rogue cells that display misfolded proteins [25]. Despite UPR being the main pathway to ER stress resolution; UPR has also been linked to autophagic flux. Autophagy can either be inhibited or activated upon ER stress [26]. Though autophagy is related to ER stress it is not always activated under ER stress conditions. Autophagy is an orchestrated process by which misfolded proteins, damaged or aged organelles, or even mutated proteins are sequestered in an autophagosome that ultimately fuses to the lysosome leading to degradation of sequestered components [27]. Reports recently have showed that withanolide E in combination with ER stress inducers enhance apoptosis synergistically in pancreatic cancer models [28]. Multiple cancer types have been reported to have increased ER stress including multiple myeloma, lung, breast, and pancreatic [29–31]. Differences in ER stress can be driven by genetic, epigenetic, and microenvironmental heterogeneity that likely result in a range of pro-survival and anti-apoptotic responses [32]. Anticancer interventions such as chemotherapy has also been shown to modulate UPR (Unfolded protein response) though clinical implications are only starting to be understood [33,34]. Recent studies have showed that depending on the context cancer cells can utilize UPR as a resistance mechanism [35].

Interestingly, overexpression of ERO1α tends to have a worse prognosis in multiple cancer indications; multiple myeloma [36], breast [37–39] and hepatocellular carcinoma [40], as well as lung, esophageal, diffuse B-cell lymphoma, and others according to The Cancer Genome Atlas (TCGA) and The Protein Atlas. These data indicate that expression is increased in aggressive and/or drug resistant disease and support the premise the ERO1α is a tractable target for the treatment of cancer. Below, we will delve into four specific topics that will reveal and shed light onto 1.) the structure, function, localization, and characterization of flavin containing ERO1α, 2.) Disease indications, 3.) immune surveillance, and immune evasion and how they are related to ERO1α and 4) chemical probes currently available to test the ERO1α-PDI pathway.

Structure, Function, Localization, and Characterization of Flavin Containing ERO1α.

Flavoenzymes are an important classification of enzymes that utilize FAD in redox reactions to maintain enzymatic function. Specifically, ERO1α promotes oxidative protein folding through PDI, producing hydrogen peroxide as a by-product and is tightly regulated to avoid futile oxidation cycles occurring in the ER [41]. There are many secretory and membrane proteins under the assistance of thiol-disulfide oxidoreductases helping form disulfide bonds in the ER [42–46]. The major players in ER oxidative reactions are ERO1α and PDI; both which are conserved from yeast to mammals [16,17,47,48]. Humans contain two ERO1 isoforms; ERO1α that is expressed in almost all cell types and ERO1β that is only expressed in select tissues. The oxidative reaction occurring between ERO1α and PDI produces hydrogen peroxide, a reactive oxygen species (ROS) [43]. Although a cell can cope with peroxides formed during basal oxidative protein folding, sometimes using them as secondary messengers in cell-signaling cascades [49] and possibly as a direct protein disulfide introducer [50,51]. If ROS production exceeds cellular capacity of antioxidants defense systems this can be harmful via introduction of ER oxidative stress [41]. ERO1α is tightly
regulated not only through phosphorylation state [52], but also through regulatory disulfide bridging. When disulfide bridges are formed between cysteine 94 and cysteine 99 ERO1α activity exceeds WT ERO1α (known as hyperactive ERO1α), whereas if cysteine 94 is bridged with cysteine 131 it leads to complete inactivity of ERO1α (Inactive ERO1α) [41]. This was shown using biochemical approaches through site-directed mutagenesis in yeast. However, this provides a potential regulatory or even compensatory mechanism that ERO1α can exploit when the ER is under extreme stress conditions. Hyperactive, inactive, and WT are the three forms of ERO1α that have been shown to exist in yeast. In yeast, cysteine 100, cysteine 105, cysteine 352, and cysteine 355 are required for oxidative reactions, whereas cysteines 90, 208, and 349 are dispensable for these functions [17]. Providing a mechanism by which cysteine 100-cysteine 105 directly engage in oxidative reactions; whereas cysteine 352-cysteine 355 serve directly to re-oxidize cysteine 100-cysteine 105. Allowing for ERO1p to undergo another oxidative reaction [16,17,41]. In humans, ERO1α catalyzes the formation of a cysteine disulfide bond as part of the FAD containing enzyme. As can be seen in Figure 2, the cysteine 397 forms a transition complex with FAD, after which cysteine 94 attacks via a nucleophilic C-S bond to form the disulfide bond, with FAD reduced to the FADH2. Cysteine 352-Cysteine 355 bridge in yeast are equivalent to Cysteine 394-Cysteine 397 in humans and undergo the same reaction process with the cofactor FAD. The regulatory cysteine bridges in yeasts (Cys100-Cys105), is also conserved in humans, and is the disulfide bridge occurring between cysteine 94-cysteine 99. This disulfide bridge in humans are responsible for accepting electrons from PDI and transferring them to the disulfide bridge between cysteine 394-cysteine 397; ultimately allowing for cysteine 397 to perform the nucleophilic attack onto bound FAD (see Figure 1 and Figure 2).

Upon successful oxidative protein folding, basal ERO1α can be shuttled into the golgi apparatus, where an interaction with FAM20C kinase occurs [52]. FAM20C is a secretory kinase founded in 2012 known for phosphorylation of the secretory protein Casein. Interestingly FAM20C prefers to use Manganese (Mn^{2+}) instead of Magnesium (Mg^{2+}) as compared to other kinases and is known for recognizing S-x-E/pS motif of secretory proteins [53,54]. It has also been shown to be insensitive to staurosporine, a known broad-spectrum kinase inhibitor. Recently, FAM20C was shown to phosphorylate ERO1α at serine residue 145 (S145). This phosphorylation state allows for 1 of 2 scenarios to take place; 1.) ERO1α can be sent extracellularly through packaging into exosomes, or 2.) Is sequestered by ERp44 (an ER transporter and chaperone protein primarily located in the endoplasmic reticulum-golgi intermediate compartment (ER-GIC) to be transferred back into the ER to undergo another oxidation cycle with PDI [55]. Zhang et al. was also able to conclude from their study that ERO1α activity was increased upon phosphorylation of residue S145, and that this reaction takes place during mammalian lactation, under hypoxia, and reductive stress conditions. Originally reported to co-localize with PDI in the ER lumen [16], ERO1α has more recently been shown to localize in the golgi apparatus [52], in proximity to the mitochondrial associated Endoplasmic Reticulum membranes (MAM), but only under oxidizing and normoxic conditions [56], and was identified from purified exosomes from bladder cancer cells, liver cancer cells, and squamous cell carcinoma cells (exocarto and protein atlas). More intriguing, ERO1α under basal conditions is still found to be localized in the ER despite not having a peptide signal sequence such as the C-terminus KDEL like
other ER-resident proteins [57]. The absence of an ER localization signal suggests that ERO1α functions may extend beyond the ER and these additional functions based on localization of the enzyme need to be discovered in order to fully understand role of ERO1α in the progression of cancer. Questions still needing to be answered are 1.) What function does ERO1α provide by being packaged into exosomes or by remaining in the golgi apparatus, and 2.) What function does ERO1α have when localized to the MAM region? Though these questions have not been answered yet fully, there has been some insight onto the function of ERO1α when localized near the MAM region. This function is to regulate Ca^{2+} flux. Downregulation of ERO1α via RNAi was found to inhibit mitochondrial Ca^{2+} fluxes and modified mitochondrial Ca^{2+} uniporters. However, upon overexpression of redox active ERO1α increased passive Ca^{2+} efflux from the ER was observed [58]. Calcium flux is an essential ER regulated process that is used in signaling, activation of apoptosis, and even used in cellular movement. Calcium is stored in the ER but released into the mitochondria for activation of apoptosis. Calcium can be transferred from the ER into the mitochondria via the MAM region and is required to maintain cellular homeostasis [59]. Thus, ERO1α functionality beyond the scope of just protein folding in the ER as localization can play pivotal roles in regulating protein function.

**Disease Indications**

Recently, ERO1α has been reported as a poor prognostic indicator in multiple cancer indications. Yang et al. showed using genetic shRNA strategies for reducing the expression of Ero1α, in HepG2 and Hep3B cells that high ERO1α expression correlated with increased migration and invasion. Moreover, these same investigators showed that in primary patient specimens high ERO1α expression was associated with poor clinicopathology of vascular invasion, metastasis, advanced Edmondson grade, and TNM stage [40]. Yang et al. were also able to conclude from their in vivo studies using HepG2 cells ectopically expressing ERO1α that an increase in metastatic burden and poor survival in vivo correlated with increased ERO1α expression and S1PR1, p-STAT3, and VEGF-A levels. However, upon depletion of ERO1α using shRNA strategies, S1PR1, p-STAT3, and VEGF-A were also reduced.

In support of clinical data indicating that ERO1α expression is a poor prognostic indicator, we probed the GEPIA database that utilizes samples from TCGA and GTEX database and compiles the data into a Kaplan-Meyer plot based on a single gene of interest. Using GEPIA, we determined that that ERO1α is considered a bad prognostic indicator in multiple cancer indications including Lung Adenocarcinoma, Hepatocellular Carcinoma, Esophageal Carcinoma, and Diffuse B-Cell Lymphoma (see Figure 3 and Table 1). Moreover, genetic and pharmacological studies in cell lines has indicated that ERO1α expression and function contributes to an aggressive cancer phenotype (see Table 1).

The GEPIA was able to confirm that high ERO1α transcript levels correlate with worse prognosis in multiple cancer indications. As mentioned previously ERO1α is responsible for protein folding. More specifically, ERO1α is directly involved in folding of membrane and secretory proteins [64]. Recently, ERO1α has also been shown to have a role in post-translational modification of β1 integrin in colorectal cancer cell when under hypoxic conditions. When ERO1α is knocked out using CRISPR Cas9 in HCT116 colorectal cancer
cells and placed under hypoxic conditions it was found that the glycosylation state of integrin β1 was changed and thus an attenuation of integrin β1 on the cell membrane occurred; ultimately leading to contact-inhibited morphology [57]. These are just a few examples of many that ERO1α is associated with cancer indications.

**Immune Surveillance and Immune Evasion Correlate with ERO1α Expression**

Recently, immuno-oncology (IO) has demonstrated to be a tractable strategy for achieving durable responses. Targets and delivery approaches which may enhance IO response with respect to percentage of patients that respond remains an active area of research (rev in [65]). As IO approaches move toward combination strategies, it is essential to determine the effect of modulating novel targets such as Ero1α on the immune tumor microenvironment. Immunotherapies have previously failed in lung cancer but has recently emerged as very effective new therapy [66], with the emergence of immune checkpoint blockade such as anti-PD-1 (programmed cell death-1) antibodies and anti PD-L1 (programmed cell death-ligand 1) antibodies [67]. ERO1α is thought to be responsible for the processing and folding of PD-L1 and PD-1. PD-L1 is a transmembrane protein located on the cell surface of placental, vascular endothelium, pancreatic islet, muscle, and mesenchymal stem cells [68], and PD-1 is a receptor belonging to the CD28 family of receptors that is only expressed on the surface of activated T-cells, B-cells, and myeloid cells [69]. The binding of PD-L1 to PD-1 is an immune suppressive signal that inhibits autoimmunity through induction of T-cell apoptosis [70] and induces tolerance [71]. Recently, a study has shown that ERO1α promotes immune escape through up-regulation of PD-L1 in breast cancer [60]. This connection is due to the intramolecular disulfide bond that exist in PD-L1 [72] and ERO1α is a known contributor to folding of membrane proteins as well as introduction of disulfide bonds [16]. In this recent finding, Tanaka et al. [60], was able to demonstrate that ERO1α up-regulates PD-L1 surface expression not only through oxidative folding, but also unexpectedly up-regulated PD-L1 mRNA expression through augmentation of hypoxia inducible factor-1alpha (HIF-1α) in human triple negative breast cancer cell lines. Although this occurrence could be diminished upon knockdown of ERO1α using RNA Interference (RNAi), as it led to significant attenuation of PD-L1 mediated T-cell apoptosis [60]. This provides insight towards hypoxia mediated immune resistance; specifically, in triple negative breast cancer cell lines. As shown previously in Figure 2, increased expression of ERO1α is a poor prognostic indicator in lung adenocarcinoma, hepatocellular carcinoma, esophageal carcinoma, and diffuse B-cell lymphoma; However, ERO1α has also be found to be a poor prognostic indicator in breast cancer by multiple researchers [37,38].

Alongside the discovery of PD-L1 and PD-1, of which Dr. Allison and Dr. Honjo won the 2018 Nobel Prize for the discovery of checkpoint blockades PD-1, PD-L1, and CTLA-4, the discovery of myeloid derived suppressor cells (MDSC’s) has also had an outstanding impact clinically. Reports of MDSC’s associated with tumor progression go back to the 1970’s [73]. However, during the 1980’s and early 1990’s, laboratories of Diana Lopez, Jim Talmadge, M. Rita Young, and Hans Schreiber, demonstrated various types of myeloid cells could inhibit immune functions in cancer [74]. There are two main groups of MDSC’s;
Polymorphonuclear MDSC’s (PMN-MDSC’s), and monocytic MDSC’s (M-MDSC’s). In recent years it has become clear that these two groups function differently in terms of immune suppression during tumorigenesis. M-MDSC’s suppress the immune system in both antigen-specific and non-specific manners utilizing mechanisms associated with production of NO and cytokines [75]. PMN-MDSC’s on the other hand can suppress immune responses primarily in an antigen-specific manner, inducing antigen specific T-cell tolerance is a major characteristic of these cells [76,77]. Recently it has been shown that tumor cells are a source of granulocytic colony stimulating factor (G-CSF) [78–81], and that production of G-CSF by tumors are responsible for recruitment of immunosuppressive PMN-MDSC’s, which promote tumor growth via inhibition of antitumor immune responses [82,83]. G-CSF is a glycoprotein that functions as a hematopoietic cytokine that is secreted from immune, endothelial and bone marrow stroma cells leading to production of granulocytes (granulopoiesis), as well as contributes to mobilization of stem cells [84]. Amongst G-CSF’s many functions, it is a secretory protein that’s folding cycle is predicted to occur through ERO1α. In a recent publication; Tanaka et al. [37] demonstrated that ERO1α plays a pivotal role in PMN-MDSC induction via up-regulation of G-CSF production from cancer cells in collaboration with PDI. Tanaka et al. [37] were also able to demonstrate that reduced expression of ERO1α through shRNA strategies reduced tumor growth by restoration of antitumor T-cell-mediated immunity, and ERO1α overexpression promoted tumor growth in vivo via suppression of antitumor immunity.

Immune system functionality has been well defined for quite some time. Despite immune system functionality being well described, cancer researchers are still discovering resistance mechanisms to cancer therapies that are utilizing the host immune system. Recently, it was found that hypoxia augmented the endogenous major histocompatibility complex I (MHC Class I) presentation in murine tumor cells [85]. MHC Class I molecules are responsible for presentation of endogenous antigens, expressed on all nucleated cells, and present protein fragment of cytosolic or nucleic nature to CD8+ T-cells on the cell membrane. [86]. These antigens are peptide fragments that are intracellular and obtained from multiple pathways being approximately 8–10 amino acids long [87]. MHC Class I molecules are stabilized by ER chaperones such as ERp57, PDI, and tapasin [86]. Upon binding of the designated peptide antigen to the MHC Class I molecule, the chaperones are released and fully assembled, peptide-MHC Class I complexes leave the ER for presentation of the cell membrane [87]. Conversely, the MHC-Class I peptide complexes that fail to associate in the ER are sent to the cytosol to undergo proteasomal mediated degradation [88,89]. Though the function of MHC Class 1 is clear, it is not clear if this function is augmented in tumors or during hypoxic conditions. HIF-1α is known to be induced under hypoxic conditions and more recently has been shown to regulate expression of ERO1α [90,91]. More specifically, ERO1α was induced in hypoxic conditions in a HIF-1α dependent manner [91]. May et al. [91] were also able to demonstrate that ERO1α was not induced under hypoxic conditions in fibroblast cell lines derived from HIF-1α knockout mice, revealing ERO1α as a transcriptional target of HIF-1α. To induce an effective antitumor immunity using cancer antigen peptide-based immunotherapy, a cancer antigen must be appropriately presented on MHC Class I molecules [37]. Kukita et al. [37] were able to determine three distinct effects that hypoxia had on MHC Class I presentation; 1.) expression of MHC Class I peptide
complex on the cell surface was augmented, 2.) activation of antigen specific CD8$^+$ T-cells was augmented, and 3.) specific cytotoxic T-lymphocytes were capable of killing tumor cells under hypoxic conditions. They were also able to determine that ERO1$\alpha$ was responsible for the hypoxia driven antigen presentation by MHC Class I molecules. ERO1$\alpha$ is responsible for the disulfide bond formation of MHC Class I heavy chains. Upon depletion of ERO1$\alpha$, MHC Class I expression on the cell surface was also shown to be decreased, resulting in decreased cytotoxic T-lymphocyte reactivity [37]. Thus, Kukita et al [37] were able to demonstrate that ERO1$\alpha$ plays a crucial role in hypoxia-induced oxidative folding of MHC Class I heavy chain, leading to augmentation of MHC Class I-peptide complex on the tumor cell surface and enhanced recognition by antigen specific cytotoxic T-lymphocytes.

Functional MHC Class I expression is needed to induce cell death via induction of CD8$^+$, T-lymphocytes. Despite increased MHC Class I expression in hypoxic conditions, the increased and chronic presence of cancer associated antigens may lead to T-cell exhaustion in hypoxic regions of the tumor, albeit further work is required to fully determine whether increased Ero1$\alpha$ expression leads to T-cell exhaustion \textit{in vivo} [92, 93]. Because inhibiting Ero1$\alpha$ is likely to change the cytokine and chemokine profile of the tumor microenvironment, further studies are required to fully understand the effect of inhibiting Ero1$\alpha$ on tumor mediated immune suppression.

**Inhibitors of the ERO1 Pathway**

Currently pharmacologic inhibitors that target ERO1$\alpha$ are limited. The first inhibitor of ERO1$\alpha$, known as EN460, and was identified through a screen of 210,960 natural compounds [94]. EN460 is specific for the reduced active form of ERO1$\alpha$ and prevents re-oxidation [94]. Our laboratory recently demonstrated that EN460 could potentially be used to treat cancers with high ER-stress such as multiple myeloma [36]. It was also confirmed during this study that EN460 had multiple off targets; all being flavoenzymes, or enzymes that contain flavin adenine dinucleotide (FAD). Our laboratory was also able to develop an azide derivative of EN-460, PB-EN-10, that showed similar effects [36]. The tool compound EN460 and its azide derivative PB-EN-10 are shown below in Figure 4. Having direct interactions with PDI during oxidative protein folding it seems feasible that PDI could also be targeted to inhibited ERO1$\alpha$ mediated biological functions. PDI has also been shown to be a potential target in multiple myeloma. Targeting PDI provides its’ own challenges as it has multiple isoforms being a family with greater than 20 members, and due to the multiple redox active cysteine residues present [95–98]. PDI inhibition currently via small molecules occurs through covalent catalysis and includes the following tool set 16F16, PACMA31, KSC-34, E61, and E64FC26 [99–102]. Despite multiple known inhibitors against PDI, none have entered clinical trials for the treatment of cancer at this time. ERO1$\alpha$ and PDI could be good targets in cancer indications if specificity could be achieved toward both enzymes, as PDI inhibitors tend to hit all PDI family members and ERO1$\alpha$ inhibitors have the tendency to target other flavoenzymes. In conclusion ERO1$\alpha$ is emerging as an attractive target for the treatment of cancer. Supporting evidence that credentials the target described above includes i) clinical data indicating that increased expression of the enzyme is a poor prognostic indicator in multiple cancer indications and ii) genetic strategies utilizing shRNA indicate that reducing the expression of ERO1L$\alpha$ inhibits growth and metastasis using both \textit{in vitro}
and in vivo model systems. However, delineation of the therapeutic window will require a drug discovery campaign to elucidate more specific and potent inhibitors to allow for further validation of the target.

Acknowledgments

Funding

5U54GM104942-04 (Hodder), R44-CA221554 (Hazlehurst) PI NCI, and NCI 1R01CA195727-01 (Hazlehurst). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC—challenges to implementing ctDNA-based screening and MRD detection. Nature Reviews Clinical Oncology. 2018 9;15(9):577–86.
2. Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discovery. 2017 12 1;7(12):1394–403. [PubMed: 28899864]
3. Nair RR, Tolentino J, Hazlehurst LA. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochemical Pharmacology. 2010 9;80(5):602–12. [PubMed: 20382130]
4. Ootsuka S, Asami S, Sasaki T, Yoshida Y, Nenoto N, Shichino H, et al. Useul markers for detecting minimal residual disease in cases of neuroblastoma. Biological and Pharmaceutical Bulletin. 2008 6;31(6):1071–4. [PubMed: 18520032]
5. Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020 4;37(4):443–55. [PubMed: 32289269]
6. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Molecular Cancer Therapeutics. 2008 10 1;7(10):3169–75. [PubMed: 18852120]
7. Osipov A, Saung MT, Zheng L, Murphy AG. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. Journal for Immunotherapy of Cancer. 2019 12 1;7(1):224. [PubMed: 31439034]
8. Westrate LM, Lee JE, Prinz WA, Voeltz GK. Form follows function: the importance of endoplasmic reticulum shape. Annual Review of Biochemistry. 2015 6;84:791–811.
9. Palade GE. Studies on the endoplasmic reticulum: II. Simple disposisions in cells in situ. The Journal of Biophysical and Biochemical Cytology. 1955 11 25;3(16):567. [PubMed: 13278367]
10. Palade GE, Porter KR. Studies on the endoplasmic reticulum: I. Its identification in cells in situ. The Journal of Experimental Medicine. 1954 11 30;100(6):641. [PubMed: 13211920]
11. Porter KR, Palade GE. Studies on the endoplasmic reticulum: III. Its form and distribution in striated muscle cells. The Journal of Cell Biology. 1957 3;25(2):269–300.
12. Mazzarello P, Calligaro A, Vannini V, Muscatello U. The sarcoplasmic reticulum: its discovery and redisclosure. Nature Reviews Molecular Cell Biology. 2003 1;4(1):69–74.
13. Schwarz DS, Blower MD. The endoplasmic reticulum: structure, function and response to cellular signaling. Cellular and Molecular Life Sciences. 2016 11;73(1):79–94. [PubMed: 26433683]
14. Moilanen A, Korhonen K, Saaranen MJ, Ruddock LW. Molecular analysis of human Ero1 reveals novel regulatory mechanisms for oxidative protein folding. Life Science Alliance. 2018 6;1(3).
15. Benham AM, Cabibbo A, Fassio A, Bulleid N, Sitia R, Braakman I. The CXXCXXC motif determines the folding, structure and stability of human Ero1-Lα. The EMBO Journal. 2000 9;19(17):4493–502. [PubMed: 10970843]
16. Cabibbo A, Pagani M, Fabbri M, Rocchi M, Farmery MR, Bulleid NJ, et al. ERO1-L, a human protein that favors disulfide bond formation in the endoplasmic reticulum. Journal of Biological Chemistry. 2000 2;275(7):4827–33.
17. Frand AR, Kaiser CA. The ERO1 gene of yeast is required for oxidation of protein dithiols in the endoplasmic reticulum. Molecular Cell. 1998 1 1(2):161–70. [PubMed: 9659913]
18. Pagani M, Fabbri M, Benedetti C, Fassio A, Pilati S, Bulleid NJ, et al. Endoplasmic reticulum oxidoreductin 1-Lβ (ERO1-Lβ), a human gene induced in the course of the unfolded protein response. Journal of Biological Chemistry. 2000 8 4:275(31):23685–92.
19. Pollard MG, Travers KJ, Weissman JS. Ero1p: a novel and ubiquitous protein with an essential role in oxidative protein folding in the endoplasmic reticulum. Molecular Cell. 1998 1 1(2):171–82. [PubMed: 9659914]
20. Bass R, Ruddock LW, Klappa P, Freedman RB. A major fraction of endoplasmic reticulum-located glutathione is present as mixed disulfides with protein. Journal of Biological Chemistry. 2004 2 13:279(7):5257–62.
21. Dixon BM, Heath SH, Kim R, Suh JH, Hagen TM. Assessment of endoplasmic reticulum glutathione redox status is confounded by extensive ex vivo oxidation. Antioxidants & Redox Signaling. 2008 5 1:10(5):963–72. [PubMed: 18205546]
22. Hwang CJ, Sinskey AJ, Lodish HF. Oxidized redox state of glutathione in the endoplasmic reticulum. Science. 1992 9 11:257(5076):1496–502. [PubMed: 1523409]
23. Tu BP, Weissman JS. Oxidative protein folding in eukaryotes mechanisms and consequences. Journal of Cell Biology. 2004 2 2;164(3):341–6.
24. Yadav U, Rani V, Deep G, Singh RK, Palle K. Oxidative stress in metabolic disorders: pathogenesis, prevention, and therapeutics.
25. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nature reviews Molecular Cell Biology. 2007 7(8):519–29. [PubMed: 17565364]
26. Rashid HO, Yadav RK, Kim HR, Chae HJ. ER stress: Autophagy induction, inhibition and selection. Autophagy. 2015 11 2;11(11):1956–77. [PubMed: 26389781]
27. Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. Nature. 2010 7:466(7302):68–76. [PubMed: 20562859]
28. Li X, Zhu F, Jiang J, Sun C, Zhong Q, Shen M, et al. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells. Autophagy. 2016 9 1:12(9):1521–37. [PubMed: 27308733]
29. Dumartin L, Alrawashdeh W, Trabulo SM, Radon TP, Steiger K, Feakins RM, et al. ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. Oncogene. 2017 6;36(22):3094–103. [PubMed: 27941872]
30. Serrano-Negrón JE, Zhang Z, Rivera-Ruiz AP, Banerjee A, Romero-Nutz EC, Sánchez-Torres N, et al. Tunicamycin-induced ER stress in breast cancer cells neither expresses GRP78 on the surface nor secretes it into the media. Glycobiology. 2018 2;28(2):61–8. [PubMed: 29206917]
31. Zhang Y, Liu R, Ni M, Gill P, Lee AS. Cell surface relocalization of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP. Journal of Biological Chemistry. 2010 5 14;285(20):15065–75.
32. Cubillos-Ruiz JR, Bettigole SE, Glimcher LH. Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer. Cell. 2013 5;150(4):692–706. [PubMed: 28187289]
33. Rutkowski DT, Arnold SM, Miller CN, Wu J, Li J, Gunnison KM, et al. Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol. 2006 11 7;4(11):e374. [PubMed: 17090218]
34. Wu J, Ruas JL, Estall JL, Rasbach KA, Choi JH, Ye L, et al. The unfolded protein response mediates adaptation to exercise in skeletal muscle through a PGC-1α/ATF6α complex. Cell Metabolism. 2011 2;13(2):160–9. [PubMed: 21284983]
35. Travers KJ, Patil CK, Wodicka L, Lockhart DJ, Weissman JS, Walter P. Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. Cell. 2000 4 28;101(3):249–58. [PubMed: 10847680]
36. Hayes KE, Batsomboon P, Chen WC, Johnson BD, Becker A, Eschrich S, et al. Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma. Bioorganic & Medicinal Chemistry. 2019 4 15:27(8):1479–88. [PubMed: 30850265]
37. Kukita K, Tamura Y, Tanaka T, Kajiwara T, Kutomi G, Saito K, et al. Cancer-associated oxidase ERO1-α regulates the expression of MHC class I molecule via oxidative folding. The Journal of Immunology. 2015 5 15;194(10):4988–96. [PubMed: 25870246]

38. Kutomi G, Tamura Y, Tanaka T, Kajiwara T, Kukita K, Ohmura T, et al. Human endoplasmic reticulum oxidoreductin 1-α is a novel predictor for poor prognosis of breast cancer. Cancer Science. 2013 8;104(8):1091–6. [PubMed: 23578220]

39. Tanaka T, Kutomi G, Kajiwara T, Kukita K, Kochin V, Kanaseki T, et al. Cancer-associated oxidoreductase ERO1-α drives the production of VEGF via oxidative protein folding and regulating the mRNA level. British Journal of Cancer. 2016 5;114(11):1227–34. [PubMed: 27100727]

40. Yang S, Yang C, Yu F, Ding W, Hu Y, Cheng F, et al. Endoplasmic reticulum resident oxidase ERO1-Lalpha promotes hepatocellular carcinoma metastasis and angiogenesis through the S1PR1/STAT3/VEGF-A pathway. Cell Death & Disease. 2018 10 30;9(11):1–4. [PubMed: 29298988]

41. Inaba K, Masui S, Iida H, Vavassori S, Sitia R, Suzuki M. Crystal structures of human Ero1α reveal the mechanisms of regulated and targeted oxidation of PDI. The EMBO Journal. 2010 10 6;29(19):3330–43. [PubMed: 20834232]

42. Alanen HI, Williamson RA, Howard MJ, Hatahet FS, Salo KE, Kauppila A, et al. ERp27, a new non-catalytic endoplasmic reticulum-located human protein disulfide isomerase family member, interacts with ERp57. Journal of Biological Chemistry. 2006 11 3;281(44):33727–38.

43. Gross E, Sevier CS, Heldman N, Viti E, Bentzur M, Kaiser CA, et al. Generating disulfides enzymatically: reaction products and electron acceptors of the endoplasmic reticulum thiol oxidase Ero1p. Proceedings of the National Academy of Sciences. 2006 11 10;103(2):299–304.

44. Hatahet F, Ruddock LW. Protein disulfide isomerase: a critical evaluation of its function in disulfide bond formation. Antioxidants & Redox Signaling. 2009 11 1;11(11):2807–50. [PubMed: 19476414]

45. Sevier CS, Kaiser CA. Disulfide transfer between two conserved cysteine pairs imparts selectivity to protein oxidation by Ero1. Molecular Biology of the Cell. 2006 5;17(5):2256–66. [PubMed: 16495342]

46. Sevier CS, Kaiser CA. Conservation and diversity of the cellular disulfide bond formation pathways. Antioxidants & Redox Signaling. 2006 5 1;8(5–6):797–811. [PubMed: 16771671]

47. Fagioli C, Mezghrani A, Sitia R. Reduction of interchain disulfide bonds precedes the dislocation of Ig-μ chains from the endoplasmic reticulum to the cytosol for proteasomal degradation. Journal of Biological Chemistry. 2001 11 2;276(44):40962–7.

48. Mezghrani A, Fassio A, Benham A, Simmen T, Braakman I, Sitia R. Manipulation of oxidative protein folding and PDI redox state in mammalian cells. The EMBO Journal. 2001 11 15;20(22):6288–96. [PubMed: 11707400]

49. Shimizu Y, Hendershot LM. Oxidative folding: cellular strategies for dealing with the resultant equimolar production of reactive oxygen species. Antioxidants & Redox Signaling. 2009 9 1;11(9):2317–31. [PubMed: 19243234]

50. Karala AR, Lappi AK, Saaranen MJ, Ruddock LW. Efficient peroxide-mediated oxidative refolding of a protein at physiological pH and implications for oxidative folding in the endoplasmic reticulum. Antioxidants & Redox Signaling. 2009 5 1;11(5):963–70. [PubMed: 19117384]

51. Karala AR, Psarrakos P, Ruddock LW, Klappa P. Protein disulfide isomerases from C. elegans are equally efficient at thiol-disulfide exchange in simple peptide-based systems but show differences in reactivity towards protein substrates. Antioxidants & Redox Signaling. 2007 11 1;9(11):1815–24. [PubMed: 17711389]

52. Zhang J, Zhu Q, Wang XE, Yu J, Chen X, Wang J, et al. Secretory kinase Fam20C tunes endoplasmic reticulum redox state via phosphorylation of Ero1α. The EMBO Journal. 2018 7 13;37(14):e98699. [PubMed: 29858230]

53. Tagliabracci VS, Engle JL, Wen J, Wiley SE, Worby CA, Kinch LN, et al. Secreted kinase phosphorylates extracellular proteins that regulate biomineralization. Science. 2012 6 1;336(6085):1150–3. [PubMed: 22582013]

54. Tagliabracci VS, Pinna LA, Dixon JE. Secreted protein kinases. Trends in Biochemical Sciences. 2013 3 1;38(3):121–30. [PubMed: 23276407]
55. Zhang L, Niu Y, Zhu L, Fang J, Wang L, Wang CC. Different interaction modes for protein-disulfide isomerase (PDI) as an efficient regulator and a specific substrate of endoplasmic reticulum oxidoreductin-1α (Ero1α). Journal of Biological Chemistry. 2014 11 7;289(45):31188–99.

56. Gilady SY, Bui M, Lynes EM, Benson MD, Watts R, Vance JE, et al. Ero1α requires oxidizing and normoxic conditions to localize to the mitochondria-associated membrane (MAM). Cell Stress and Chaperones. 2010 9 1;15(5):619–29. [PubMed: 2086508]

57. Takei N, Yoneda A, Sakai-Sawada K, Kosaka M, Minomi K, Tamura Y. Hypoxia-inducible ERO1α promotes cancer progression through modulation of integrin-β1 modification and signalling in HCT116 colorectal cancer cells. Scientific Reports. 2017 8 24;7(1):1–1. [PubMed: 28127051]

58. Anelli T, Alessio M, Bachi A, Bergamelli L, Bertoli G, Camerini S, et al. Thiol-mediated protein retention in the endoplasmic reticulum: the role of ERp44. The EMBO journal. 2003 10 1;22(19):5015–22. [PubMed: 14517240]

59. Szymański J, Janikiewicz J, Michałska B, Patalas-Krawczyk P, Perrone M, Ziolkowski W, et al. Interaction of mitochondria with the endoplasmic reticulum and plasma membrane in calcium homeostasis, lipid trafficking and mitochondrial structure. International Journal of Molecular Sciences. 2017 7;18(7):1576.

60. Tanaka T, Koutomi G, Kaijara T, Kukita K, Kochin V, Kanaseki T, et al. Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer. Oncotarget. 2017 4 11;8(15):24706. [PubMed: 28160557]

61. Lee S, Lee E, Ko E, Ham M, Lee HM, Kim ES, et al. Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-α and MMP-9. Cancer Letters. 2018 11 28;437:25–34. [PubMed: 30165193]

62. Chang LC, Hsieh MT, Yang JS, Lu CC, Tsai FJ, Tsao JW, et al. Effect of bis (hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study. International Journal of Oncology. 2017 12 31;52(1):67–76. [PubMed: 29138806]

63. Wang Y, Zhang L, He Z, Deng J, Zhang Z, Liu L, et al. Tunicamycin induces ER stress and inhibits tumorigenesis of head and neck cancer cells by inhibiting N-glycosylation. American Journal of Translational Research. 2020;12(2):541. [PubMed: 32194902]

64. Wang PF, Veine DM, Ahn SH, Williams CH. A stable mixed disulfide between thioredoxin reductase and its substrate, thioredoxin: preparation and characterization. Biochemistry. 1996 4 16;35(15):4812–9. [PubMed: 864271]

65. Goldberg MS. Improving cancer immunotherapy through nanotechnology. Nature Reviews Cancer. 2019 10;19(10):587–602. [PubMed: 31492927]

66. Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology. 2016 7;21(5):821–33. [PubMed: 27101251]

67. Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, et al. Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study. Journal of Clinical Oncology. 2017 7 1;35(19):2117. [PubMed: 28375787]

68. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Molecular Cancer Therapeutics. 2015 4 1;14(4):847–56. [PubMed: 25695955]

69. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clinical Cancer Research. 2007 9 15;13(18):5271–9. [PubMed: 17875575]

70. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. The Journal of Experimental Medicine. 2000 10 2;192(7):1027–34. [PubMed: 11015443]

71. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. Journal of Experimental Medicine. 2006 4 17;203(4):883–95.

72. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nature Reviews Cancer. 2013 10;13(10):739–52. [PubMed: 24060865]
73. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo: Presented in part at the Keystone Symposium “Cellular and Molecular Biology of Dendritic Cells,” Santa Fe, NM, March 3–9, 1998, and at the annual meeting of the American Association for Cancer Research, March 28-April 1, 1998. Blood, The Journal of the American Society of Hematology. 1998 12;92(11):4150–66.

74. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Research. 2007 1;67(1):425–.

75. Koehn BH, Apostolova P, Haerverkamp JM, Miller JS, McCullar V, Tolar J, et al. GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood, The Journal of the American Society of Hematology. 2015 9;24;12(13):1621–8.

76. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity. 2010 6;25(6):790–802. [PubMed: 20605485]

77. Asano Y, Yokoyama T, Shibata S, Kobayashi S, Shimoda K, Nakashima H, et al. Effect of the chimeric soluble granulocyte colony-stimulating factor receptor on the proliferation of leukemic blast cells from patients with acute myeloblastic leukemia. Cancer Research. 1997 8;57(16):3395–7. [PubMed: 9270003]

78. Chakraborty A, Guha S. Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells. Urology. 2007 6;69(6):1210–5. [PubMed: 17572226]

79. Joshita S, Nakazawa K, Sugiyama Y, Kimijo A, Matsubayashi K, Miyabayashi H, Furuta K, Kitano K, Kawa S. Granulocyte colony-stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course. International Medicine. 2009;48(9):687–91. [PubMed: 19420814]

80. Savedese TM, Mitchell K, McQuain C, Campbell CL, Guardiani R, Wuu J, et al. Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. Cancer letters. 2001 1;162(1):105–15. [PubMed: 11121868]

81. Abrams SI, Waigh JD. Identification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression. Oncoimmunology. 2012 7;1(4):550–1. [PubMed: 22754783]

82. Waigh JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PloS one. 2011 11;6(11):e27690. [PubMed: 22110722]

83. Pedersen CC, Borup R, Fischer-Nielsen A, Mora-Jensen H, Fossum A, Cowland JB, et al. Changes in gene expression during G-CSF–induced emergency granulopoiesis in humans. The Journal of Immunology. 2016 9;197(5):1989–99. [PubMed: 27481851]

84. Kajiwara T, Tanaka T, Kukita K, Kato E, Saito K, Okuya K, et al. Hypoxia augments MHC class I antigen presentation via facilitation of ERO1-α-mediated oxidative folding in murine tumor cells. European Journal of Immunology. 2016 12;46(12):2842–51. [PubMed: 27667124]

85. Neefjes J, Jongsma ML, Paul P, Bakke O. The known unknowns of antigen processing and presentation. Nature Reviews Immunology. 2011 12;11(12):823–36.

86. Wyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nature Reviews Immunology. 2008 8(8):607–18.

87. Hughes EA, Hammond C, Cresswell P. Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. Proceedings of the National Academy of Sciences. 1997 3;94(5):1896–901.

88. Koopmann JO, Albring J, Hütter E, Bulbuc N, Spee P, Neefjes J, et al. Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. Immunity. 2000 7;13(1):117–27. [PubMed: 10933400]

89. Gess B, Hofbauer KH, Wenger RH, Lohaus C, Meyer HE, Kurtz A. The cellular oxygen tension regulates expression of the endoplasmic oxidoreductase ERO1-Lα. European Journal of Biochemistry. 2003 5;270(10):2228–35. [PubMed: 12752442]
90. May D, Itin A, Gal O, Kalinski H, Feinstein E, Keshet E. Ero1-L α plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer. Oncogene. 2005 2;24(6):1011–20. [PubMed: 15592500]

91. Mueller SN, Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proceedings of the National Academy of Sciences. 2009 5 26;106(21):8623–8.

92. Richter K, Brocker T, Oxenius A. Antigen amount dictates CD 8+ T-cell exhaustion during chronic viral infection irrespective of the type of antigen presenting cell. European Journal of Immunology. 2012 9;42(9):2920–304. [PubMed: 22653665]

93. Blais JD, Chin KT, Zito E, Zhang Y, Heldman N, Harding HP, et al. A small molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1) with selectively reversible thiol reactivity. Journal of Biological Chemistry. 2010 7 2;285(27):20993–1003.

94. Edman JC, Ellis L, Blacher RW, Roth RA, Rutter WJ. Sequence of protein disulphide isomerase and implications of its relationship to thioredoxin. Nature. 1985 9 19;317(6034):267–70. [PubMed: 3840230]

95. Foster CK, Thorpe C. Challenges in the evaluation of thiol-reactive inhibitors of human protein disulfide Isomerase. Free Radical Biology and Medicine. 2017 7 1;108:741–9. [PubMed: 28465261]

96. Watanabe MM, Laurindo FR, Fernandes DC. Methods of measuring protein disulfide isomerase activity: a critical overview. Frontiers in Chemistry. 2014 9 3;2:73. [PubMed: 25232538]

97. Yang S, Shergalis A, Lu D, Kyani A, Liu Z, Ljungman M, et al. Design, synthesis, and biological evaluation of novel allosteric protein disulfide isomerase inhibitors. Journal of Medicinal Chemistry. 2019 2 13;62(7):3447–74. [PubMed: 30759340]

98. Cole KS, Grandjean JM, Chen K, Witt CH, O’Day J, Shoulders MD, et al. Characterization of an A-site selective protein disulfide isomerase A1 inhibitor. Biochemistry. 2018 3 9;57(13):2035–43. [PubMed: 29521097]

99. Hoffstrom BG, Kaplan A, Letso R, Schmid RS, Turmel GJ, Lo DC, et al. Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins. Nature Chemical Biology. 2010 12;6(12):900–6. [PubMed: 21079601]

100. Robinson RM, Reyes L, Duncan RM, Bian H, Strobel ED, Hyman SL, et al. Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor. European Journal of Medicinal Chemistry. 2020 1 15;186:111906. [PubMed: 31787362]

101. Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, et al. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proceedings of the National Academy of Sciences. 2012 10 2;109(40):16348–53.

102. Kim KM, An AR, Park HS, Jang KY, Moon WS, Kang MJ, et al. Combined expression of protein disulfide isomerase and endoplasmic reticulum oxidoreductin 1 α is a poor prognostic marker for non small cell lung cancer. Oncology Letters. 2018 11 1;16(5):5753–60. [PubMed: 30344729]
Figure 1:
Upon Phosphorylation of Serine 145 by FAM20C Kinase, ERO1α can return to the endoplasmic reticulum (ER). Above is an illustration of the interaction occurring between active site of ERO1α, PDI, and Glutathione (GSH). This reaction is also capable of occurring in the reverse direction resulting in redox equilibrium inside the ER. (Red circle is the phosphorylation site of ERO1α at serine 145 via FAM20C kinase, Black squares connected by blue lines are active disulfide bridges required for redox to occur, and black arrows are representative of electron flow when ERO1α is being reduced.)
Figure 2:
A) The structure of ERO1a (3AHQ.pdb) with the FAD binding site shown; B) the orientation of the Cys394-Cys397 with FAD; C) the proposed catalytic scheme of FAD and disulfide bond formation.
Figure 3:
Top Left Panel represents survival data for Lung Adenocarcinoma in respect to ERO1α, Top Right Panel represents Esophageal Carcinoma, Bottom Left Panel represents survival data for hepatocellular carcinoma, and Bottom Right Panel represents survival data for diffuse B-cell lymphoma. Kaplan-Meyer Plots above were plotted using ERO1α gene filter in GEPIA, which obtains data from TCGA and GTEx databases.
Figure 4:
Structure of EN460, the first ERO1α inhibitor, and the azide derivative PB-EN-10.
| Cancer Type               | Cell Type                      | Native ERO1α expression | Tools used                                      | Native expression effect/silencing effect                                                                 | Reference(s) |
|--------------------------|--------------------------------|-------------------------|------------------------------------------------|-----------------------------------------------------------------------------------------------------------|---------------|
| Breast                   | 9A3, 9C1, 9C2                  | Comparable to MDA-MB-231| † ERO1α ‡ ERO1α/shRNA                            | † PD-L1; dependent on oxidative folding                                                                 | [60]          |
| Breast                   | MDA-MB-231, 9A3, 9C1, 9C2      | Comparable to MDA-MB-231| † ERO1α ‡ ERO1α/shRNA                            | † angiogenic potential via VEGF secretion, † tumor growth                                                                 | [39]          |
| Breast                   | MCF10A                         | Comparable to MCF-7     | † ERO1α ‡ ERO1α/shRNA                            | Tumor associated Macrophages increased ERO1α expression, causing † MMP-9 expression, and † invasion | [61]          |
| Breast                   | 4T1                            | Comparable to healthy mouse mammary tissue; Healthy human breast tissue | † ERO1α ‡ ERO1α/shRNA                            | † ERO1α expression lead to † tumor burden; † ERO1α ‡ MDSC’s and leads to immune evasion | [37]          |
| Breast                   | 4T1 Triple negative patient samples | Comparable to healthy mouse mammary tissue; Healthy human breast tissue | † ERO1α/shRNA                                    | ♦ tumor burden, ♦ lung metastasis; Patients with † ERO1α expression had worse prognosis overall. | [38]          |
| Breast                   | MDA-MB-231                     | Comparable to MDA-MB-468| † ERO1α ‡ ERO1α/shRNA                            | MTH-3 treatment lead to ‡ ERO1α, activation of autophagy, and lead to apoptosis                         | [62]          |
| Hepatocellular Carcinoma | Patient samples, LO2, Huh-7, HEP3B, SMMC-7721, HEPG2, MHCC-97H | ERO1α expression lower in healthy tissue compared to tumor samples and cell lines | † ERO1α/shRNA † ERO1α                               | † ERO1α lead to less metastasis and decreased tumor burden. † ERO1α lead to increase metastatic potential and increased tumor burden. | [40]          |
| Head and Neck            | HN4, CAL27                     | -                       | † ERO1α/shRNA                                    | Tunicamycin treatment † ER stress, † ERO1α expression, and † overall tumor burden                       | [63]          |
| Multiple Myeloma         | Patient samples U266, MM1.5     | Increased ERO1α expression poor prognostic indicator in multiple myeloma | Chemical EN-460 PB-EN-10                          | Pharmacological inhibition Erol α lead apoptosis and ER stress in U266 myeloma cell line                | [36]          |

(*) indicates no available data